“The FDA’s clearance of our IND for BD200 is a significant step toward advancing the first multibody into clinical testing,” said Yanay Ofran, Ph.D., CEO and founder of Biolojic Design. “In addition to marking an important milestone in the evolution of multi-specific antibodies, it is also an important achievement in the application of AI to drug design by showing that AI can support the creation of antibodies with unique properties and potentially transformative capabilities. We look forward to starting our Phase 1 study in the coming weeks.”